

Vaccines and Global Health: The Week in Review 03 May 2025 :: Issue 796 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy

david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to <u>david.r.curry@centerforvaccineethicsandpolicy.org</u>.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: <u>Journal Watch</u>
- :: Pre-Print Servers
- :: Think Tanks
- :: Public Consultations/Call for Inputs/Call for Papers

Milestones, Perspectives

......

Measles - PAHO

28 April 2025 | Measles - Region of the Americas

Situation at a glance

As of 18 April 2025, a total of 2318 measles cases, including three deaths, have been confirmed in six countries in the WHO Region of the Americas, an 11-fold increase compared to the same period in 2024. The majority of cases have occurred among people between 1 to 29 years, who are either unvaccinated or have an unknown vaccination status. Additionally, most cases are imported or linked to importation. Measles is a highly contagious, airborne viral disease that can lead to severe complications and death. Although it is preventable with two doses of the vaccine, over 22 million children worldwide did not receive their first dose of the vaccine in 2023. This has contributed to a global rise in measles cases in 2024, which heightens the risk of imported infections, particularly from unvaccinated travellers arriving from areas where the virus is actively circulating. WHO is working closely with countries in the WHO Region of the Americas to prevent the spread and reintroduction of measles. The regional risk is currently assessed as high, while the global risk remains moderate.

[Overview by countries at title link above]

Public health response

- Regional and National Public Health Authorities in the Americas Region are implementing public health measures to control the outbreak, and WHO is providing support by:
- Issuing epidemiological alerts and updates due to the increase in measles cases in several countries in the WHO Region of the Americas that started in 2024.
- Issuing the Public Health Risk Assessment related to measles in the region of the Americas, classified the risk as "High", especially in countries with low vaccination coverage.
- Continuing to monitor the situation and work closely with countries in the Region of the Americas to support their vaccination, surveillance and rapid outbreak response efforts to prevent the spread and reintroduction of measles and to protect the health of the entire population.
- Providing technical assistance and follow-up with laboratories in countries that have had cases/outbreaks.
- Strengthening countries' rapid response capacities by 1) training healthcare workers in rapid response to outbreaks, using hybrid workshops and virtual courses; 2) providing financial funds for international consultants' deployment in the most affected areas in LAC; 3) having virtual follow-up meetings with countries.
- Promoting mass follow-up vaccination campaigns in countries with highly susceptible populations to rapidly reduce the risk of the reintroduction of endemic measles and rubella in the countries of the Region.
- Enhancing risk communication and community engagement in countries where outbreaks have occurred, to reinforce their commitment to immunization and recommended actions.





Figure 2: Geographical distribution of the confirmed cases between 1 January- 18 April 2025



WHO risk assessment

In the WHO Region of the Americas, in 2025, there is an 11-fold increase in the number of cases compared to the same period in 2024. Although an improvement has been achieved in measles rubella surveillance indicators, there are still countries that do not meet the minimum notification rate of two suspected cases per 100 000 population, in addition to other indicators, in a homogeneous way. This could delay detection, notification, confirmation, and rapid response actions.

Difficulty in maintaining adequate levels of vaccination in the migrant population, vaccine-hesitant groups and other at-risk populations within the Region are big challenges. Given that several countries in Europe, Central Asia and Africa have areas of circulation of the virus, the identification of imported cases from these areas is expected. Intense migration from areas where the disease is endemic to areas where it is not could increase the risk of new outbreaks and cases. Considering population movement, international travel and mass gathering events, the risk of international spread cannot be ruled out. Travellers from regions with ongoing outbreaks can introduce the virus into countries with higher vaccination coverage, where there are still vulnerable populations, particularly infants who may not yet have received their first dose of the measles vaccine.

The overall risk of measles in the Americas Region is considered high due to several factors:

- Ongoing virus circulation from imported cases has led to outbreaks with extended transmission chains, secondary cases, and virus spread to new areas and countries in 2025.
- Suboptimal vaccination coverage persists across the region. In 2023, only 28.6% of countries achieved over 95% coverage for the first MMR dose (MMR1), and just 16.7% for the second dose (MMR2). Regional coverage was 87% for MMR1 and 76% for MMR2. Data for 2024 is still being consolidated.
- An increasing number of susceptible individuals due to continued low coverage, driven by factors like the COVID-19 pandemic, vaccine hesitancy, and limited access to healthcare, especially among vulnerable groups such as migrants, displaced persons, and Indigenous populations.

The overall risk of this event in the WHO Region of the Americas, especially in countries with low vaccination coverage, is classified as high with a high confidence level based on available information.

The overall risk at the global level is assessed as moderate due to the ongoing transmission in all the other WHO Regions, where immunization programs in several countries are not at an optimal level due to various factors, such as resource limitations, vaccine hesitancy, political instability, and health system weaknesses.

WHO advice

WHO recommends maintaining sustained homogeneous coverage of at least 95% with the first and second doses of the measles-containing vaccine (MCV) and strengthening integrated epidemiological surveillance of measles and rubella to achieve timely detection of all suspected cases in public and private healthcare facilities.

WHO recommends strengthening epidemiological surveillance and preparedness and rapid response capacities in high-traffic border areas to rapidly detect and respond to suspected measles cases. Providing a rapid response to imported measles cases to avoid the re-establishment of endemic transmission through the activation of rapid response teams trained for this purpose and by implementing rapid response protocols when there are imported cases. Once a rapid response team has been activated, continued coordination between the national, sub-national and local levels must be ensured, with continuous and effective communication channels across all levels. During outbreaks, it is

recommended to establish adequate hospital case management and infection prevention and control capacity to avoid health care-associated infection transmission, with appropriate referral of patients to airborne infection isolation rooms (for any level of care) and avoiding contact with other patients in waiting rooms and/or other hospital rooms.

WHO recommends providing broad access to measles, mumps, and rubella (MMR) or measles and rubella (MR) vaccination to maintain high vaccination rates of the general population and to ensure individuals at high risk of exposure are up to date on this vaccination, such as health and care personnel and international travellers. Individuals living in outbreak areas should follow local public health guidance. Globally, between 2000 and 2023, vaccination successfully prevented an estimated 60 million deaths (6 million deaths in the Americas) and decreased an estimated measles death from 800 062 in 2000 to 107 500 in 2023, which is an 87% decrease.

WHO recommends maintaining a stock of the MR and/or MMR vaccines, and syringes/supplies for responding to imported cases. Facilitating access to vaccination services according to the national scheme to incoming and outgoing international travellers, including individuals due to perform activities, domestically or abroad, in areas with ongoing measles outbreaks, displaced populations, indigenous populations, or other vulnerable populations.

WHO advises international travellers to check and update their vaccination status against measles prior to departure. Unvaccinated individuals from areas experiencing measles outbreaks, with knowledge of exposure to measles cases and/or presenting signs and symptoms compatible with measles virus infection, should consult local health authorities before undertaking an international voyage. At present, no additional measures that significantly interfere with international traffic are warranted.

::::::::

U.S. Administration Actions – Vaccines/Immunization

HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses May 01, 2025

Washington, D.C. – The U.S. Department of Health and Human Services (HHS) and the National Institutes for Health (NIH) today announced the development of the next-generation, universal vaccine platform, Generation Gold Standard, using a beta-propiolactone (BPL)-inactivated, whole-virus platform.

This initiative represents a decisive shift toward transparency, effectiveness, and comprehensive preparedness, funding the NIH's in-house development of universal influenza and coronavirus vaccines, including candidates BPL-1357 and BPL-24910. These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses like H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV...

Generation Gold Standard, developed exclusively by NIH's National Institute of Allergy and Infectious Diseases (NIAID):

- Recalibrates America's pandemic preparedness. Unlike traditional vaccines that target specific strains, BPL-inactivated whole-virus vaccines preserve the virus's structural integrity while eliminating infectivity. This approach induces robust B and T cell immune responses and offers long-lasting protection across diverse viral families. Moreover, the intranasal formulation of BPL-1357 is currently in Phase Ib and II/III trials and is designed to block virus transmission—an innovation absent from current flu and COVID-19 vaccines.

- **Embodies efficient, transparent, and government-led research.** The BPL platform is fully government-owned and NIH-developed. This approach ensures radical transparency, public accountability, and freedom from commercial conflicts of interest.
- **Marks the future of vaccine development**. In addition to influenza and coronavirus, the BPL platform is adaptable for future use against respiratory syncytial virus (RSV), metapneumovirus, and parainfluenza. It also offers the unprecedented capability to protect against avian influenza without inducing antigenic drift—a major step forward in proactive pandemic prevention.

Clinical trials for universal influenza vaccines are scheduled to begin in 2026, with FDA approval targeted for 2029. The intranasal BPL-1357 flu vaccine, currently in advanced trials, is also on track for FDA review by 2029.

::::::::

Editor's Note:

HHS and the HHS Secretary made announcements over the last week which were reported in the media but were not formalized in press releases or published statements. Given their importance and potential impacts on public health, we assess that these media reports warrant timely inclusion here.

RFK Jr. will order placebo testing for new vaccines, alarming health experts

The Washington Post, Updated May 1, 2025

The potential change outlined in a statement would require all new vaccines to undergo placebo testing, sparking concerns among medical experts...

The administration will require all new vaccines to be tested against an inert substance known as a placebo before they can be made available, which is a "radical departure from past practices," according to a statement from Andrew Nixon, a spokesman for Robert F. Kennedy Jr., the secretary of Health and Human Services...

[We have not identified a posted version of the HHS statement referenced in this report]

US Health secretary Kennedy revives misleading claims of 'fetal debris' in measles shots

Reuters, May 1, 2025 9:21 PM EDT

By Ahmed Aboulenein and Nancy Lapid

Summary

- :: Kennedy claims measles vaccine contains fetal cells, despite scientific evidence
- :: Comments coincide with expanding measles outbreak in Texas
- :: Measles outbreak in Texas linked to vaccine hesitancy

WASHINGTON, May 1 (Reuters) - U.S. health secretary Robert F. Kennedy Jr. reprised various misleading claims about vaccines this week, including that the measles vaccine contains cells from aborted fetuses and the mumps vaccination does not work.

Kennedy's comments come as the U.S. battles one of its worst outbreaks of measles in 25 years. Scientists have warned that the U.S. is at a <u>tipping point</u> for the return of endemic measles, declared eradicated nationally in 2000, and say U.S. public health officials like Kennedy should provide urgent endorsement for highly effective vaccines...

<u>Kennedy Orders Search for New Measles Treatments Instead of Urging Vaccination</u> New York Times, May 2, 2025

Decades of research have turned up no miracle treatment for measles, but studies show the M.M.R. shot is 97 percent effective in preventing the disease.

::::::::

Most of the Public Oppose Major Federal Cuts to Health Agencies and Programs and Say They Have Been Made "Recklessly"

The Public, Including Most Republicans, Oppose Medicaid Cuts; MAGA Supporters Are Divided Kaiser Family Foundation May 1, 2025 News Release [Excerpt]

Large Majorities Oppose Specific Cuts to Federal Health Programs and Agencies

The poll also gauges the public's views on federal funding cuts for other health programs. In each case, more than six in 10 oppose specific federal health cuts. For example:

- About three quarters (74%) oppose major cuts to states for mental health and addiction prevention services. This includes a narrow majority of Republicans (58%), and large majorities of Democrats (89%) and independents (75%).
- Most (71%) oppose major cuts to funding to track infectious disease outbreaks. This
 includes half of Republicans (51%), and large majorities of Democrats (89%) and independents
 (74%).
- Seven in 10 (69%) oppose major cuts to research at universities and medical centers. This includes large majorities of Democrats (92%) and independents (69%). In contrast, most Republicans (56%) favor such cuts.
- Nearly two thirds (65%) oppose reduced federal funding to help people pay the premiums for health coverage purchased through the Affordable Care Act marketplaces. This includes large majorities of Democrats (88%) and independents (65%). In contrast, most Republicans, (61%) favor such cuts.

Majorities Across Partisans Oppose Major Cuts to Social Security, Medicare, Medicaid, and Mental Health Services

Percent who say they **oppose** major cuts to federal funding:

	Total	Democrats	Independents	Republicans
For Social Security	84%	94%	85%	73%
For Medicare	79%	94%	81%	64%
For Medicaid	76%	95%	79%	55%
To states for mental health and addiction prevention services	74%	89%	75%	58%
For tracking infectious disease outbreaks	71%	89%	74%	51%
For research at universities and medical centers	69%	92%	69%	44%
For HIV prevention programs	65%	89%	66%	39%
To help people who purchase health coverage through the Affordable Care Act pay their premiums	65%	88%	65%	39%

Note: See topline for full question wording. Source: KFF Health Tracking Poll (Apr. 8-15, 2025)

KFF

Polio – PHEIC

::::::::

Headlines

:: World Immunization Week 2025, themed 'Immunization for All is Humanly Possible', wrapped up 30 April. The annual campaign coordinated by WHO aims to promote uptake of vaccines, raise awareness about their importance, safety and effectiveness, and encourage action to improve immunization access worldwide. During the week, we saw lot of buzz and great content on polio eradication — thank you to all who engaged with it. To view some of this content, please check out the WHO Polio X account and the new GPEI LinkedIn page. Be sure to like, follow and share!
:: Health ministers from across the Eastern Mediterranean Region met virtually with GPEI partners on 27 April for the 13th meeting of the Regional Subcommittee for Polio Eradication and Outbreaks, renewing an urgent call to end polio in the Region. More.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Pakistan: two WPV1 cases and 22 WPV1-positive environmental samples
- Nigeria: three cVDPV2 cases

::::::::

Health ministers renew urgent call to end polio in the Eastern Mediterranean Region

Regional leaders call for intensified support to stop wild poliovirus transmission in Afghanistan and Pakistan

28 April 2025 – Health ministers from across the Eastern Mediterranean Region and Global Polio Eradication Initiative (GPEI) partners convened virtually on 27 April for the 13th meeting of the Regional Subcommittee for Polio Eradication and Outbreaks, reaffirming the Region's collective solidarity to end polio, the longest running Public Health Emergency of International Concern.

Convened by WHO's Regional Director for the Eastern Mediterranean and co-chaired by the health ministers of Qatar and the United Arab Emirates, the Subcommittee has, over the past 4 years, become a pivotal regional platform for rallying support and concerted actions to reach zero polio.

Despite significant progress, more than 100 children have been paralysed by wild poliovirus in Afghanistan and Pakistan over the past year. Variant poliovirus outbreaks continue in Djibouti, Gaza and Somalia and vaccination campaigns have been suspended in the northern governorates of Yemen since 2021. Conflict, humanitarian crises, insecurity and climate change have added complexity to the epidemiological situation...

.....

mPox - PHEIC

Multi-country outbreak of mpox, External situation report #51 - 29 April 2025

Cases of mpox due to clade Ib monkeypox virus (MPXV) continue to be reported primarily in Africa, where eleven countries have reported community transmission of this strain in the past six weeks

KEY FIGURES								
Reporting period: 1 January 2022 – 31 March 2025								
Area	Number of reported confirmed cases		Number of deaths among confirmed cases	Number of reporting countries				
Global	137 892		317	132				
Reporting period: 1 January 2024 – 20 April 2025								
Area	Number of reported confirmed cases		Number of deaths among confirmed cases ¹					
	2024	2025	2024	2025				
Africa	20 009	10 944	45	63				
Democratic Republic of the Congo ²	15 067	5197	27	22				
Uganda	1353	4033	7	33				
Burundi	2946	866	1	0				
Reporting period: last six v	weeks, 10 March – 2	0 April 2025						
Africa	2896		29					
Democratic Republic of the Congo	807		7					
Uganda	1343		18					
Burundi	198		0					

Mpox vaccination in the African Region

As of 22 April 2025, seven African countries have initiated mpox vaccination, all using MVA-BN vaccine. A total of 662 740 doses have been administered during the current outbreak response. Notably, 88% of these doses have been administered in the Democratic Republic of the Congo, the country reporting the highest number of cases.

Given the supply-constrained context of current outbreaks in Africa, WHO recommends the off-label use of a single dose or intradermal fractional dosing of MVA-BN vaccine. At its March 2025 meeting, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) re-emphasized the importance of dose sparing strategies during times of vaccine shortages in outbreak response situations. This approach is also reflected in the recently updated Strategic Preparedness and Response Plan (SPRP) for mpox.

Below is a summary of countries that have started mpox vaccination, the number of doses administered to date, and the target populations... [Country summaries at title link above]

Vaccines

- WHO continues to provide strategic, guidance, and technical support to accelerate implementation and uptake of mpox vaccination in affected countries for people at risk, in support of controlling the surge in mpox cases on the African continent.
- To date, 1 045 180 vaccine doses have been delivered to ten countries, including 50 000 doses of LC16m8 vaccine from Japan to the Democratic Republic of the Congo in January 2025.
- Vaccination activities have started in seven countries (the Central African Republic, Democratic Republic of the Congo, Liberia, Nigeria, Rwanda, Sierra Leone, and Uganda). Other countries seeking vaccine allocations are preparing national mpox vaccination plans.
- The position of the vaccine manufacturer Bavarian Nordic on product liability for MVA-BN mpox vaccine: When national regulatory authorities allow age indications which are not on the label of the product (e.g. one year and above, or 12 years and above) in their Marketing Authorization (MA)

- or Emergency Use Authorization (EUA), Bavarian Nordic covers the product liability for these age groups.
- WHO, UNICEF and the International Federation of Red Cross and Red Crescent Societies (IFRC)
 have produced a resource on "How to achieve and sustain high uptake of mpox vaccination in
 outbreak settings". April 2025.
- The AAM partners continue to work together to ensure countries receive guidance to get operational funds for implementation of the national vaccination plans.

::::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: <u>WHO</u>

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::::

WHO & Regional Offices [to 04 May 2025]

https://www.who.int/news

Selected News/Announcements/Statements

GOARN marks 25 years of advancing global health emergency preparedness and response 28 April 2025

News release, Geneva

The <u>Global Outbreak Alert and Response Network (GOARN)</u>, an initiative coordinated by the World Health Organization (WHO), marks its 25th anniversary today. Since its inception in April 2000, the network has been at the forefront of the global fight against health emergencies. By leveraging the expertise of global partners – facilitating alerts, deploying rapid support capacities, and strengthening capacities – it has significantly enhanced country-level operations and strengthened regional development, playing a critical role in health preparedness and response...

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region AFRO

:: 01 May 2025

Scaling up response to anthrax outbreak in the Democratic Republic of the Congo

:: 25 April 2025

Digitalization is revolutionising Mozambique's malaria response

WHO Region of the Americas PAHO

:: 2 May 2025

<u>PAHO inaugurates Emergency Operations Centre in Barbados to strengthen Caribbean</u> <u>health security</u>

Bridgetown, Barbados, 2 May 2025 (PAHO) – The Pan American Health Organization (PAHO) officially inaugurated the Carissa F. Etienne Emergency Operations Centre (EOC) at its Barbados office, a state-of-the-art facility designed to coordinate health emergency preparedness and response across Barbados, the Eastern Caribbean, and the wider Caribbean."...

:: 30 Apr 2025

New PAHO report reveals that 14 countries in the Americas face health worker shortages

Without intervention, the Region could face a deficit of between 600 000 and 2 million health workers by 2030Washington, D.C., 30 April 2025 (PAHO) - A new report from the Pan American Health Organization (PAHO), The Health Workforce in the Americas: Regional Data and Indicators, reveals that 14 out of 39 countries in the Americas lack...

:: 30 Apr 2025

<u>PAHO and UNOPS sign new agreement to promote and strengthen health systems in Latin</u> America and the Caribbean

Panama City, April 30, 2025 - The United Nations Office for Project Services (UNOPS) and the Pan American Health Organization/World Health Organization (PAHO/WHO) have signed a new Memorandum of Understanding (MoU) aimed at reinforcing the collaboration between the two organizations and optimizing the execution of health sector projects in...

:: 28 Apr 2025

Disease elimination takes center stage at Vaccination Week in the Americas launch

Panama City, Panama, April 28, 2025 (PAHO) – The 23rd edition of Vaccination Week in the Americas commenced today in Panama City, underscoring the pivotal role of immunization in achieving and sustaining the elimination of communicable diseases across the Region."Since 2003, Vaccination Week in the Americas has been a cornerstone of our Region's...

WHO South-East Asia Region SEARO

No new digest content identified.

WHO European Region EURO

2 May 2025 News release

<u>T cells to the rescue! Immune Patrol education package rolls out in schools across the WHO European Region</u>

1 May 2025 News release

Public health advice for visitors attending the Jubilee 2025 in Italy

30 April 2025 News release

<u>Improving health security by removing barriers to vaccination – progress at the local level in the European Region</u>

WHO Eastern Mediterranean Region EMRO

- :: <u>Health ministers renew urgent call to end polio in the Eastern Mediterranean Region</u> 28 April 2025
- :: Pakistan and WHO renew their pledge to protect millions with lifesaving vaccines
 27 April 2025

WHO Western Pacific Region

No new digest content identified.

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

Multi-country outbreak of mpox, External situation report #51 - 29 April 2025

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

28 April 2025 | Measles - Region of the Americas

::::::

Weekly Epidemiological Record

Vol. 100, Nos. 18, pp. 145-154 2 May 2025

https://www.who.int/publications/journals/weekly-epidemiological-record

:: Strengthening global health security: the role of national International Health Regulations focal points in the 2024 Oropouche virus outbreak

::::::

New WHO Publications

https://www.who.int/publications

Selected

1 May 2025

<u>Strengthening hand hygiene practices in community settings and health-care facilities in the context...</u>

29 April 2025

Progression pathway for governance of mixed health systems

29 April 2025

Report of the virtual regional consultation on yaws eradication in Africa, 11-12 April 2024

29 April 2025

Global Antimicrobial Resistance and Use Surveillance System (GLASS) report: antibiotic use data for...

::::::

::::::

USA - HHS, FDA, CDC+

Editor's Note:

We employ bolded red text below to identify observations we assess might be useful to readers. Please see expanded treatment at <u>Milestones</u>, <u>Perspectives</u> above.

HHS

News

HHS, NIH Launch Next-Generation Universal Vaccine Platform for Pandemic-Prone Viruses
May 01, 2025

NIH

News Releases

HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses

May 1, 2025 — These vaccines aim to provide broad-spectrum protection against multiple strains of multiple viruses.

NIH to prioritize human-based research technologies

Tuesday, April 29, 2025 - New initiative aims to reduce use of animals in NIH-funded research.

FDA

<u>Press Announcements</u> No new digest content identified.

CDC/ACIP [U.S.] [to 04 May 2025]

http://www.cdc.gov/media/index.html Latest News No new digest content identified.

ACIP Meetings [to 04 May 2025]

Next ACIP Meetings
:: June 25-26
:: October 22-23

MMWR Weekly

https://www.cdc.gov/mmwr/index2025.html May 1, 2025 / No. 15

PDF of this issue

No new digest content identified.

FDA VRBPAC

Advisory Committee Calendar

The Advisory Committee calendar does not list any future scheduled meetings of VRBPAC. One other advisory committee meeting has been added to the overall calendar in the last week.

National Vaccine Program

https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
No 2025 meeting dates posted.

Advisory Commission on Childhood Vaccines (ACCV)

https://www.hrsa.gov/advisory-committees/vaccines/meetings

Next ACCV Meeting - TBD

We are rescheduling the ACCV Meetings originally planned for Wednesday, January 29, 2025, and Thursday, January 30, 2025. Once the new dates are confirmed, information will be available here on the ACCV website and announced in the Federal Register.

::::::

Europe

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en
News/Updates/Reports/Publications [Selected]
Surveillance and monitoring

Communicable disease threats report, 26 April - 3 May 2025, week 18

2 May 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 26 April - 3 May 2025 and includes updates on respiratory virus epidemiology in the EU/EEA, SARS-CoV-2, chikungunya virus disease, diphtheria, mpox, influenza A(H5N1), cholera, yellow fever, and Ebola disease.

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news

News & Press Releases

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025

16 new medicines recommended for approval; another ten medicines recommended for extension of their therapeutic indications

25 April 2025

::::::

Africa CDC [to 04 May 2025]

https://africacdc.org/

Press Releases, Statements [Selected]

Press Releases

Africa CDC Warns: Millions of African Children Still Lack Access to Life-Saving Vaccines

30 April 2025

Press Releases

Africa CDC Commends Uganda's Leadership in Ending Eighth Ebola Outbreak 27 April 2025

::::::

China CDC+

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 04 May 2025]

http://en.nhc.gov.cn/

News

<u>China's National Health Commission answers questions on white paper from press</u> 2025-04-30 / Xinhua

China's State Council Information Office on Wednesday released a white paper titled "Covid-19 Prevention, Control and Origins Tracing: China's Actions and Stance." The National Health Commission has responded to questions raised by the press regarding the white paper.

<u>China releases white paper on Covid-19 prevention, control and origins tracing</u>
<u>Full text: Covid-19 Prevention, Control and Origins Tracing: China's Actions and Stance</u>

National Medical Products Administration – PRC [to 04 May 2025]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (7)

2025-05-02 / No. 18 NATIONAL MALARIA DAY ISSUE

View PDF of this issue

- Commentary: Malaria Ends with Us Time to Reinvest, Reimagine, and Reignite
- <u>Vital Surveillances: Risk Factors for Imported Severe Malaria Cases China, 2019–2023</u>
- <u>Methods and Applications: Global Assistance and the Cascade of Malaria Prevention and Control —</u> <u>Sub-Saharan Africa, 2011–2022</u>
- <u>Methods and Applications: Impact of Implementation Interruptions of 1,7-Malaria Reactive</u>
 <u>Community-Based Testing and Response Approach on Malaria Control Efforts Southern Tanzania</u>
- Review: China's Malaria R&D Innovations: A Scoping Review from 2013–2023

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [to 04 May 2025]

https://alleninstitute.org/ news-press/

News

No new digest content identified.

BMGF - Gates Foundation [to 04 May 2025]

https://www.gatesfoundation.org/ideas/media-center Press Releases & Statements No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 04 May 2025]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications

No new digest content identified.

CARB-X [to 04 May 2025]

https://carb-x.org/

News

04.30.2025 |

CARB-X releases 2024 Annual Report celebrating a year of progress

CARB-X today published its 2024 Annual Report, highlighting critical action to address antimicrobial resistance (AMR). The report outlines how CARB-X continues to strengthen the antibacterial development ecosystem and accelerate research and development.

Chan Zuckerberg Initiative [to 04 May 2025]

https://chanzuckerberg.com/newsroom/

Newsroom

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 04 May 2025]

http://cepi.net/ CEPI News, Blog No new digest content identified.

CIOMS - COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 04

May 2025]

https://cioms.ch/

News; Publications; Events

<u>Public Consultation - Artificial Intelligence in Pharmacovigilance</u>

CIOMS Working Group XIV

You are invited to participate in the Public Consultation during 1 May – 6 June 2025. All comments on the <u>draft report</u> of the CIOMS Working Group XIV on Artificial intelligence in pharmacovigilance must be provided using this comment form in Word format.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 04 May 2025]

https://www.darpa.mil/news

News

No new digest content identified.

DNDI – Drugs for Neglected Diseases initiative [to 04 May 2025]

https://dndi.org/press/press-releases/

Press Releases

No new digest content identified.

Duke Global Health Innovation Center [to 04 May 2025]

https://dukeghic.org/

News

Mpox Transparency and Accountability for the Global Response

May 1, 2025

Welcome to the thirteenth issue of our report, "Mpox: Transparency and Accountability for the Global Response." In the wake of the U.S. health agencies' communications and foreign aid fre...

QuickStart COVID-19 Test and Treat resources leveraged to support Marburg and Mpox <u>response in Rwanda</u>

April 29, 2025

Rwanda's Ministry of Health leveraged COVID-19 resources, established through the QuickStart COVID-19 Test-and-Treat Initiative, to respond to the Marburg Virus Disease (MDV) and Claude 1b M...

EDCTP [to 04 May 2025]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials No new digest content identified.

Emory Vaccine Center [to 04 May 2025]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

European Vaccine Initiative [to 04 May 2025]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Fondation Merieux [to 04 May 2025]

http://www.fondation-merieux.org/

News, Events

Événement co-organisé par la Fondation Mérieux & l'Université de Genève

25ème Cours avancé de vaccinologie (ADVAC)

5-16 mai 2025 - Centre des Pensières, Veyrier-du-Lac (France)

Événement co-organisé par la Fondation Mérieux

<u>3ème édition du cours avancé sur l'épidémiologie dans les situations d'urgence complexes</u> 7-11 juillet 2025 - Cenre des Pensières, Veyrier-du-Lac (France)

Gavi [to 04 May 2025] https://www.gavi.org/

Press Releases

Global Summit: Health & Prosperity through Immunisation

Brussels, Belgium | 25 June 2025

Gavi's high-level pledging summit, to be co-hosted by the European Union and the Gates Foundation, seeks to raise at least US\$ 9 billion from our donors to fund our ambitious strategy to protect 500 million children, saving at least 8 million lives from 2026–2030, protect our world from the threat of pandemics, and protect communities from conflict, climate change and other global challenges.

Gavi delivers largest shipment yet to DRC in support of international mpox response

- :: The latest shipment of 200,000 mpox vaccine doses from Gavi, the Vaccine Alliance, will arrive this week in the Democratic Republic of the Congo (DRC) to support outbreak response.
- :: As the largest contributor of vaccines to the global Access and Allocation Mechanism (AAM) for mpox, Gavi has provided nearly half a million doses to nine African countries to date

:: Additionally, Gavi has facilitated nearly 250,000 dose donations and made more than US\$ 6.2 million available to countries to cover delivery of doses and vaccination activities 1 May 2025

Portuguese Government strengthens support for global health with €2.5 million pledge – a 54% increase in contributions – to Gavi, the Vaccine Alliance

1 May 2025

Nearly half a million children in Bangladesh miss full immunization, despite 81.6% coverage: Gavi, UNICEF, and WHO urge immediate action for equity

GE2P2 Global Foundation [to 04 May 2025]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review May 2025
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 25 April 2025
- :: Genomics :: Governance, Ethics, Policy, Practice A Monthly Digest April 2025

GHIT Fund [to 04 May 2025]

https://www.ghitfund.org/newsroom/press

Press Releases

April 23, 2025

<u>Investment of Approx. USD 4.5 Million in Development of Diagnostics for Tuberculosis to</u>
Partners including Fujirebio and University Hospital Heidelberg

Global Fund [to 04 May 2025]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 04 May 2025]

https://www.glopid-r.org/news/

News

GloPID-R's Data Sharing Working Group Launches a Visionary Implementation Guide

Annecy, France – April 30, 2025 – At a two-day in-person meeting of the GloPID-R Data Sharing Morking Group, held in Annecy on April 29–30, 2025, the group officially launched its suite of implementation tools, including a dedicated GloPID-R Data Sharing Implementation Guide — a forward-looking and practical tool to help research funders support their grantees in sharing research data during outbreaks....

Hilleman Laboratories [to 04 May 2025]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 04 May 2025]

https://www.hhmi.org/news

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 04 May 2025]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [to 04 May 2025]

https://www.iavi.org/

Press Releases, Features

IAVI Report

Picking up the pieces

May 1, 2025

Funding, staffing, and policy changes by the U.S. government trigger a major blow to vaccine research and international collaborations that were decades in the making.

Features

IAVI applauds Ugandan health authorities on the end of the country's Sudan virus outbreak

April 29, 2025

Uganda's comprehensive public health response included a ring vaccination trial of IAVI's investigational Sudan virus vaccine candidate.

INSERM [to 04 May 2025]

https://www.inserm.fr/en/home/

Press Releases

No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news

Selected Statements, Press Releases, Research

No new digest content identified.

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 04 May 2025]

https://www.ich.org/

News/Pubs/Press Releases [Selective]

ICH Meeting in Madrid, Spain

Madrid, Spain 13 - 14 May 2025

The Assembly of the International Council for Harmonisation (ICH) will convene in person from 13 - 14 May 2025, in Madrid, Spain and will be preceded by meetings of the ICH Management Committee and the MedDRA Management Committee.

For more information, please click here.

Or	ngoing Public	c Consultations	^
>	M11 EWG	Clinical electronic Structured Harmonised Protocol (CeSHarP)	
>	M13B EWG	Bioequivalence for Immediate-Release Solid Oral Dosage Forms	
>	Q1 EWG	Stability Testing of Drug Substances and Drug Products	

https://www.ich.org/page/public-consultations

ICRC [to 04 May 2025]

https://www.icrc.org/en/whats-new

Latest press releases and statements [Selected]

<u>Israel and the occupied territories: After two months of aid blockage, humanitarian</u> response in Gaza on verge of total collapse

News release 02-05-2025

ICRC President: "Taking part in the Global Initiative to Galvanize Political Commitment to International Humanitarian Law is taking a stand against wars without rules"

Statement 02-05-2025

We must not only remember the past but learn from it and take urgent action to prevent the unspeakable from happening again

Statement 30-04-2025

Resolution on 'Protecting civilians and other protected persons and objects against the potential human cost of ICT activities during armed conflict'

Article 29-04-2025

In October 2024, all states and National Red Cross and Red Crescent Societies convened in Geneva for the 34th International Conference of the Red Cross and Red Crescent Movement.

In this unique humanitarian forum, participants adopted a groundbreaking resolution on "Protecting civilians and other protected persons and objects against the potential human cost of ICT activities during armed conflict.

The resolution presents a shared concern about the harm caused by the use of ICT activities during armed conflict, a commitment to protect the civilian population against ICT threats during armed conflict, and highlights key IHL obligations that all belligerents must respect in their use of ICTs...

IFFIm [to 04 May 2025]

http://www.iffim.org/

Press Releases/Announcements

<u>IFFIm increases its most recent bond by US\$ 250 million to total US\$ 1.25 billion</u> 23 Apr 2025

This week, the International Finance Facility for Immunisation (IFFIm) increased by US\$ 250 million the October 2024 bond, which had previously raised US\$1 billion.

IFRC [to 04 May 2025]

http://media.ifrc.org/ifrc/news/press-releases/

Press releases

Press release 02/05/2025

IFRC Emergency Appeal launched as Afghan returnee crisis escalates

Press release 28/04/2025

Myanmar earthquake one-month on: needs remain massive

IPPS - International Pandemic Preparedness Secretariat [to 04 May 2025]

https://ippsecretariat.org/news/

News

No new digest content identified.

Institut Pasteur [to 04 May 2025]

https://www.pasteur.fr/en/press-area

Press Documents

Press release 28.04.2025

<u>HIV: genetic characteristics associated with sustained HIV remission after stopping treatment</u>

Tackling HIV continues to be a major public health challenge, mainly because the persistence of viral reservoirs means...

ISC / International Science Council [to 04 May 2025]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

STI Forum 2025: 10th Multi-stakeholder Forum on Science, Technology and Innovation for the Sustainable Development Goals

The theme for the STI Forum 2025 is "Advancing sustainable, inclusive, and evidence-based, science and technology solutions and innovations for the 2030 Agenda and its SDGs for leaving no one behind."

New panel of experts to tackle gender gap in science leadership

Although progress has been made, women continue to be underrepresented in leadership positions across scientific organizations globally. To address this persistent gap, an international panel of experts has been established to guide a major study aimed at identifying barriers, highlighting effective practices, and informing structural reforms to advance gender equality in science.

April 29, 2025

International Union of Immunological Societies (IUIS)

https://iuis.org/

News/Events [Selected]

19th International Congress of Immunology

Vienna, August 17-22, 2025.

IVAC [to 04 May 2025]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 04 May 2025]

http://www.ivi.int/

IVI News & Announcements

Prof. Pierre van Damme and Dr. Ananda Sankar Bandyopadhyay as co-awardees; and Ms. Luiza Helena Trajano and Ms. Svetha Janumpalli co-awardees honored at 2025 IVI – SK bioscience Park MahnHoon Award Ceremony

Johns Hopkins Center for Health Security [to 04 May 2025]

https://centerforhealthsecurity.org/newsroom Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 04 May 2025]

http://www.msf.org/

Latest [Selected Announcements]

Myanmar

One month since devastating earthquake in Myanmar

Voices from the Field 2 May 2025

Gaza-Israel war

Gaza, inside the war

MSF. 28 Apr 2025

Conflict in Sudan

Action must be taken now to avert worsening malnutrition crisis in South Darfur

Press Release 28 Apr 2025

National Academy of Medicine - USA [to 04 May 2025]

https://nam.edu/programs/

News [Selected]

No new digest content identified

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 04 May 2025]

https://www.nationalacademies.org/newsroom

News

<u>Systematic and Nationally Coordinated Approach for Newborn Blood Spot Screening Is</u> <u>Needed, Says New Report</u>

Leadership and coordination are needed at the national level to build on the strength of newborn screening programs that test babies for serious health conditions.

Date - 2025-05-01

Type - News Release

PATH [to 04 May 2025]

https://www.path.org/media-center/

Newsroom [Selected]

No new digest content identified.

Sabin Vaccine Institute [to 04 May 2025]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [to 04 May 2025]

http://www.unaids.org/en News, Stories, Updates Feature Story

<u>Impact of the US funding cuts: A snapshot on HIV commodity availability and management risks</u>

01 May 2025

The sudden pause and suspension of US Government foreign assistance has resulted in a multifactorial increase in the risks, challenges, and uncertainty related to HIV commodity^[1] availability and management.

The analysis below presents findings from 56 countries (including 100% of PEPFAR-supported countries) which reported on the status of their HIV commodity stocks and supply chains between February and April 2025.^[2]

The nature of PEPFAR support is different in all countries, and inclusion in this fact sheet does not necessarily mean that PEPFAR funded HIV commodities or supply chains specifically in that country. This fact sheet reflects the situation based on information available as of 28 April 2025. Given the rapidly shifting situation, the information presented could change significantly as the situation evolves...

UNICEF [to 04 May 2025]

https://www.unicef.org/media/press-releases Latest press releases, news notes and statements [Selected] No new digest content identified.

Unitaid [to 04 May 2025] https://unitaid.org/ Featured News No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 04 May 2025]

https://vaccineequitycooperative.org/news/ News

No new digest content identified.

Vaccine Confidence Project [to 04 May 2025]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center - Children's Hospital of Philadelphia [to 04 May 2025]

http://www.chop.edu/centers-programs/vaccine-education-center

News

Vaccine Update Newsletter April 2025

Wellcome Trust [to 04 May 2025]

https://wellcome.org/news/all
News. Opinion, Reports
Analysis

Ignacio Vázquez

Is policy keeping up with science and technology breakthroughs?

30 April 20257-minute read

Explainer

<u>Tuberculosis is curable and preventable – why do millions still die?</u>

28 April 2025

The Wistar Institute [to 04 May 2025]

https://www.wistar.org/news/press-releases

Press Releases April 30, 2025

The Wistar Institute Announces the Appointment of Xiaoyu (Ariel) Zhou, Ph.D., to Vaccine & Immunotherapy Center

PHILADELPHIA — (April 30, 2025) —The Wistar Institute, a world leader in cancer, immunology, and infectious disease research, announces the appointment of Xiaoyu (Ariel) Zhou, Ph.D., as assistant professor...

World Bank [to 04 May 2025]

http://www.worldbank.org/en/news/all

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 04 May 2025]

https://www.wfpha.org/

Blog, Events

No new digest content identified.

World Medical Association [WMA]_[to 04 May 2025]

https://www.wma.net/news-press/press-releases/

Press Releases

The World Medical Association Condemns the Detention and Abduction of Health Professionals in Sudan

30.04.2025

World Organisation for Animal Health [OIE] [to 04 May 2025]

https://www.oie.int/ Press Releases, Statements No new digest content identified.

::::::

ARM [Alliance for Regenerative Medicine] [to 04 May 2025]

https://alliancerm.org/press-releases/ Selected Press Releases No new digest content identified.

BIO [to 04 May 2025]

https://www.bio.org/press-releases

Press Releases

No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 04 May 2025]

http://www.dcvmn.org/ News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 04 May 2025]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [to 04 May 2025]

https://ifpma.org/

News, Statements [Selected] Statement 2 May 2025

<u>UN Multi-stakeholder Hearing on the Prevention and Control of Noncommunicable</u>
<u>Diseases (NCDs) and the Promotion of Mental Health and Well-being</u>

International Alliance of Patients' Organizations – IAPO [to 04 May 2025]

https://www.iapo.org.uk/news
Press and media [Selected]
No new digest appropriate ide

No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/

News

No new digest announcements identified.

PhRMA [to 04 May 2025]

http://www.phrma.org/

Press Releases

No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified.

Bavarian Nordic

Latest News May 02, 2025

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

Bharat Biotech

<u>Press Releases</u> - No new digest announcements identified.

BioCubaFarma – Cuba

Últimas Noticias

Reafirman BioCubaFarma y China lazos de cooperación en biotecnología

Resumen: Visita de delegación china al Complejo Industrial Biotecnológico CIGB-Mariel evidencia los importantes resultados, en una primera etapa, del Centro Conjunto China-Cuba en Biotecnología de Yongzhou, en cuanto a: incubación de proyectos de investigación y desarrollo, generación de nuevos datos científicos y publicaciones en revistas especializadas, registros de patentes conjuntas y formación de capital humano altamente calificado.

Lun, 24/03/2025 - 13:43

Biological E

<u>News</u> - No new digest announcements identified.

BioNTech

<u>Press Releases</u> - No new digest announcements identified.

Boehringer

<u>Press Releases</u> - No new digest announcements identified.

CanSinoBIO

<u>News</u> - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

CinnaGen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

<u>News</u> - No new digest announcements identified.

Curevac

<u>News</u> - No new digest announcements identified.

Gamaleya National Center/Sputnik

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020] https://sputnikvaccine.com/ - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

GSK makes strong start to 2025 with growth in sales, profits and earnings

30 April 2025

[Vaccines sales £2.1 billion (-6%); Shingrix £0.9 billion (-7%); Meningitis vaccines £0.4 billion (+20%); and Arexvy £0.1 billion (-57%)

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

JNJ Innovative Medicine [Janssen]

Press Releases - No new digest announcements identified

Merck

News releases

Merck Announces First-Quarter 2025 Financial Results

[GARDASIL/GARDASIL 9 Sales Declined 41% to \$1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40%1

Moderna

Press Releases

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates May 1, 2025

[Commercial Updates

- :: COVID-19: The Company reported \$84 million in Spikevax® sales in the first quarter of 2025, which includes \$29 million of U.S. sales and \$55 million of international sales. As previously reported, Moderna entered into a tender opportunity in January to compete for COVID vaccine business in the EU.
- :: RSV: The Company reported \$2 million in mRESVIA® sales in the first quarter of 2025. Moderna's RSV vaccine for adults aged 60 years and older has been recently approved in Australia, Switzerland, Taiwan and the UK.'

Nanogen

News - No new digest announcements identified.

Novartis

News - No new digest announcements identified on website.

Novavax

Press Releases

Apr 23, 2025

Statement COVID-19

Latest update on U.S. FDA BLA for Novavax's COVID-19 Vaccine

Apr 28, 2025

Last week, Novavax responded to the formal communication received from the U.S. Food and Drug Administration (FDA) for our Biologics License Application (BLA) and our response addresses the request for a postmarketing commitment (PMC) for a clinical trial. PMCs by their nature are completed after BLA approval. PMCs are not unusual with many approved drugs and/or biologics having at least one PMC or requirement. We believe our application is approvable upon alignment on the details of the PMC. We look forward to continued engagement with the FDA.

Pfizer

Recent Press Releases - No new digest announcements identified.

R-Pharm

https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur

<u>Press Releases</u> - No new digest announcements identified.

Serum Institute

News & Announcements - No new digest announcements identified.

Sinopharm/WIBPBIBP

News - No new digest announcements identified.

Sinovac

Press Releases

SINOVAC Announces New Board Member and Chairman of the Audit Committee

2025/04/30

BEIJING – Sinovac Biotech Ltd. (NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that its board of directors (th

SK Biosciences

Press Releases

No new digest announcements identified

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

Press Releases

April 26, 2025

<u>Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by</u> <u>French Authorities</u>

Saint Herblain (France), April 26, 2025 – <u>Valneva SE</u> (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation for use of Valneva's single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus (CHIKV) following reports of serious adverse events (SAEs) in elderly people with comorbidities during the ongoing vaccination campaign in La Reunion and Mayotte. Valneva has been responding to the French government's call for

vaccine supply of IXCHIQ® in La Reunion[1] as the island is going through a major chikungunya outbreak with $\sim 40,000$ confirmed cases since the beginning of 2025[2].

The authorities initially prioritized vaccination of adults aged 65 and over, especially those with comorbidities. On April 25, the French health authorities decided to suspend the use of IXCHIQ® in persons aged 65 years and older pending further investigation. This is a response to an ongoing investigation of three cases of SAEs resulting in hospitalization, including one death, after vaccination with IXCHIQ® among people in La Reunion...

Vector State Research Centre of Viralogy and Biotechnology

<u>Home</u> - [Website not responding [404 error]

WestVac Biopharma

Media - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

:: Milestones, Perspectives

:: WHO

:: Organization Announcements

:: Journal Watch

:: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 16, 2025 Issue 1 https://www.tandfonline.com/toc/uabr21/current [Reviewed earlier]

AMA Journal of Ethics

Volume 27, Number 5: E303-391 May 2025 https://journalofethics.ama-assn.org/issue/private-equity-health-care

Issue Theme: Private Equity in Health Care

One way private equity differs from other for-profit investments is by aiming to maximize profitability while minimizing long-term holdings in such investments. Valuation for private equity acquisitions in health care has grown to over 150 billion dollars since 2020, and expansion continues. One reason private equity investment in the health sector deserves close ethical attention is that private equity firms are, generally, not interested in managing patient panels, clinician personnel, or making service delivery streams work for patients. Another reason is that influx of private equity investment in health care tends to consolidate markets for health services, undermining competition and driving up costs for patients. This theme issue considers which criteria should be used to determine whether, when, and for whom buying and selling of private equity in health care stands up to ethical, clinical, and legal scrutiny and considers how to better guide and regulate private equity transactions in health care.

Case and Commentary

When and How Should Patients Be Informed About Clinicians' or Organizations' Sale of a Clinical Practice to a Private Equity Buyer?

Cheryl Erwin, PhD, JD and Sheryl Tatar Dacso, DrPH, JD, MPH

Private equity firms' acquisition and management of physicians' practices have been associated with increased cost and diminished quality.

American Journal of Human Genetics

May 01, 2025 Volume 112 Issue 5 p965-1248

https://www.cell.com/ajhg/current

This month in *The Journal*

Alyson B. Barnes, Sara B. Cullinan

More than 90% of individuals have at least one actionable pharmacogenomic (PGx) variant and associated drug contraindication. Most individuals, however, are unaware of their PGx status at first prescription, increasing the odds of adverse reactions or poor drug metabolism. In this issue, Lanting et al. leverage existing biobank data to develop individualized PGx passports containing comprehensive PGx information for variants in 12 genes. These PGx passports were shared with 1,227 biobank participants through a smartphone application.

Perspectives

<u>Increasing the genomic workforce through research capacity building: Designing</u> evaluation plans for maximum impact

Karyn J. Roberts, et al.

Prospective evaluation plans for research efforts are required for ongoing evaluation, quality improvement, and adjustment of implementation strategies. By sharing our methods for creating an a priori evaluation plan, we provide a framework for others to consider as they work to increase diversity and build research capacity in the genomics workforce.

American Journal of Infection Control

May 2025 Volume 53 Issue 5 p537-668 http://www.ajicjournal.org/current
Major Articles

<u>Isolation precautions associated with COVID-19 infections among immunocompromised populations: A multicenter study of nine National Cancer Institute--designated Comprehensive Cancer Centers</u>

Marie H. Wilson, et al.

Published online: February 14, 2025

p596-601

American Journal of Preventive Medicine

May 2025 Volume 68 Issue 5 p859-1050 https://www.ajpmonline.org/current [New issue; No digest content identified]

American Journal of Public Health

May 2025 115(5) http://ajph.aphapublications.org/toc/ajph/current EDITORIALS

<u>Leveraging Lessons Learned From the COVID-19 Pandemic to Support Vaccine Adherence</u>

Sarah R. MacEwan PhD

EDITOR'S CORNER

<u>"We Who Believe in Freedom Cannot Rest": Affirming the Call to Critically Engage Public Health</u>

Lisa Bowleg PhD

Protecting Public Health in the Courts

Wendy E. Parmet JD

American Journal of Tropical Medicine and Hygiene

Volume 112 (2025): Issue 4 (Apr 2025) https://www.ajtmh.org/view/journals/tpmd/112/4/tpmd.112.issue-4.xml [Reviewed earlier]

Annals of Internal Medicine

April 2025 Volume 178, Issue 4 https://www.acpjournals.org/toc/aim/current [Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 341 April 2025 https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C [Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/ (Accessed 04 May 2025) [No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content (Accessed 04 May 2025 [No new digest content identified]

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 04 May 2025) [No new digest content identified]

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content (Accessed 04 May 2025) [No new digest content identified]

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 04 May 2025) [No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 04 May 2025)

The impact of SARS-CoV-2 infection on vaccinated versus unvaccinated pregnant women: a retrospective cohort study

Pregnant women were included in the COVID-19 vaccination strategy adopted in Spain in May 2021. We evaluated the obstetric and neonatal symptoms and complications presented by these first pregnant women infect...

Authors: Noelia Rodríguez-Blanco, Jesús Sánchez-Más, Estela Gimenez Herrero, Paloma Calvo Moreno,

Macarena Mateo Gonzalez-Román and José Luis Duro-Torrijos

Citation: *BMC Pregnancy and Childbirth* 2025 25:519 Content type: Research Published on: 30 April 2025

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles (Accessed 04 May 2025)

<u>Impacts of local, provincial, and federal immigration policies on health and social services access among women with precarious immigration status</u>

Im/migrant women (e.g., non-status immigrants, refugee claimants, students, temporary foreign workers, visitors, and other migrants) face structural barriers to health and social services access. While immigra...

Authors: Hanah Damot, Shaina Schafers, Mei-ling Wiedmeyer, Stefanie Machado, Elmira Tayyar,

Padmini Thakore, Ruth Lavergne and Shira Miriam Goldenberg

Citation: BMC Public Health 2025 25:1570

Content type: Research Published on: 28 April 2025

Measuring (Mis)trust in the age of COVID-19: viewpoints of vaccine clinical trial participation among individuals living with sickle cell disease

COVID-19 vaccine efficacy was determined by the participation of individuals from diverse backgrounds in clinical trials. While these trials recruited participants with chronic conditions, little is known abou... Authors: Khadijah Abdallah, Kiana Amini, Hasmin C. Ramirez, Madison Keller, Diba Seddighi, Marilyn S. Baffoe-Bonnie, Shameka Thomas, Vence L. Bonham and Ashley J. Buscetta

Citation: BMC Public Health 2025 25:1568

Content type: Research Published on: 28 April 2025

Low Hepatitis B vaccination coverage in New Delhi, India: urgent call for Universal Adult Hepatitis B vaccination

Eliminating Hepatitis B by 2030 is achievable through vaccination. However, despite the safety of the Hepatitis B vaccine, vaccination coverage among adults in India is suboptimal.

Authors: Kanica Kaushal, Sumridhi Gautam, Priyanka Aggarwal, Guresh Kumar, Shantanu Dubey and

Shiv Kumar Sarin

Citation: BMC Public Health 2025 25:1560

Content type: Research Published on: 26 April 2025

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 04 May 2025) [No new digest content identified]

BMJ Evidence-Based Medicine

April 2025 - Volume 30 - 2 https://ebm.bmj.com/content/30/2 [Reviewed earlier]

BMJ Global Health

April 2025 - Volume 10 - 4 https://gh.bmj.com/content/10/4 [Reviewed earlier]

Bulletin of the World Health Organization

2025 Mar 1; 103(3) https://www.who.int/publications/journals/bulletin/ [Reviewed earlier]

Cell

May 01, 2025 Volume 188 Issue 9 p2307-2560 https://www.cell.com/cell/current [New issue; No digest content identified]

Child Care, Health and Development

Volume 51, Issue 3 May 2025 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 117, Issue 4 Pages: 859-1148 April 2025 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

[Reviewed earlier]

Clinical Therapeutics

May 2025 Volume 47 Issue 5 p337-402 http://www.clinicaltherapeutics.com/current [New issue; No digest content identified]

Clinical Trials

Volume 22 Issue 2, April 2025 https://journals.sagepub.com/toc/ctja/22/2 [Reviewed earlier]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 04 May 2025] [No new digest content identified]

Contemporary Clinical Trials

Volume 151 April 2025 https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/151/suppl/C [Reviewed earlier]

The CRISPR Journal

Volume 8, Issue 2 / April 2025 https://www.liebertpub.com/toc/crispr/8/1 [Reviewed earlier]

Current Genetic Medicine Reports

Volume 13, Issue 1 December 2025 https://link.springer.com/journal/40142/volumes-and-issues/13-1 [Reviewed earlier]

Current Medical Research and Opinion

Volume 41, Issue 3 2025 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

April 2025 - Volume 38 - Issue 2 https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx [Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 04 May 2025]

[No new digest content identified]

Developing World Bioethics

Volume 25, Issue 1 Pages: 1-79 March 2025

https://onlinelibrary.wiley.com/toc/14718847/current

[Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024 https://www.tandfonline.com/toc/cdip20/34/6 [Reviewed earlier]

Development Policy Review

Volume 43, Issue 3 May 2025 https://onlinelibrary.wiley.com/toc/14677679/current [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 19 - 2025

 $\underline{https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-medicine-and-public$

<u>issue</u>

[Reviewed earlier]

Disasters

Volume 49, Issue 3 July 2025 https://onlinelibrary.wiley.com/toc/14677717/current [Reviewed earlier]

eBioMedicine

Volume 114 In progress (April 2025) https://www.sciencedirect.com/journal/ebiomedicine/vol/113/suppl/C [Reviewed earlier]

EMBO Reports

Volume 26 Issue 7 7 April 2025 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 31, Number 4—April 2025 http://wwwnc.cdc.gov/eid/ [Reviewed earlier]

Epidemics

Volume 50 March 2025 https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 153 - 2025

https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue

[Reviewed earlier]

Ethics & Human Research

Volume 47, Issue 2, Pages: 1-47, March–April 2025 https://onlinelibrary.wiley.com/toc/25782363/current

Community engagement in South Africa :: Research ethics training for youth researchers

Articles Open Access

<u>Expectations, Tensions, and Brokerage: A Discourse Analysis of Community Engagement</u> with Health Research in South Africa

Sonja Klingberg, Catherine E. Draper

Pages: 2-15

First Published: 14 March 2025

<u>Building Ethical Foundations in Research: Adaptation of a Research Ethics Training</u> Program for Adolescents

Angela K. S. Gummadi, Kirstin Griffin, Farah Contractor, Jessica Forrester, Irène P. Mathieu

Pages: 34-40

First Published: 14 March 2025

Ethics & International Affairs

Volume 38 - Issue 4 - Winter 2024 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 32 2024

https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc [Reviewed earlier]

The European Journal of Public Health

Volume 35, Issue 1, February 2025 https://academic.oup.com/eurpub/issue/35/1 [Reviewed earlier]

Expert Review of Vaccines

Volume 24, 2025 Issue 1

https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

May/June 2025 Volume 104, Number 3 https://www.foreignaffairs.com/issues/2025/104/3 [Reviewed earlier]

Forum for Development Studies

Volume 52, 2025 - Issue 1 http://www.tandfonline.com/toc/sfds20/current **Co-creating knowledge in development studies**[Reviewed earlier]

Frontiers in Genetics

https://www.frontiersin.org/journals/genetics [Accessed 04 May 2025] [No new digest content identified]

Frontiers in Genome Editing

https://www.frontiersin.org/journals/genome-editing [Accessed 04 May 2025] [No new digest content identified]

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463 [Accessed 04 May 2025] [No new digest content identified]

Gene Therapy – Nature

Volume 32 Issue 2, March 2025 https://www.nature.com/gt/volumes/32/issues/2 [Reviewed earlier]

Genetics in Medicines

Volume 27, Issue 4 April 2025 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/4 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 04 May 2025] [No new digest content identified]

Global Health Action

Volume 18, Issue 1 (2025) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 6 December 20, 2024 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/ https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc [Accessed 04 May 2025] [No new digest content identified]

Global Public Health

Volume 20, Issue 1 (2025) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 04 May 2025] [No new digest content identified]

Health and Human Rights

Volume 26, Issue 2, December 2024 https://www.hhrjournal.org/volume-26-issue-2-december-2024/ **Special Section: Distress Migration and the Right to Health** [Reviewed earlier]

Health Economics, Policy and Law

Volume 20 - Issue 1 - January 2025 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 40, Issue 4, May 2025 https://academic.oup.com/heapol/issue/40/4 Reviews Editor's Choice

<u>Factors influencing the establishment of hospital accreditation programs in low- and middle-income countries: a scoping review</u>

Dilantha Dharmagunawardene and others *Health Policy and Planning*, Volume 40, Issue 4, May 2025, Pages 496–517, https://doi.org/10.1093/heapol/czaf011

Health Research Policy and Systems

http://www.health-policy-systems.com/content

[Accessed 04 May 2025]

<u>Convergence and diversity: how collective risk perception shapes public compliance behaviour – a case study of China's Covid-19 response</u>

This study investigates the influence of collective risk perception on public compliance behaviour, aiming to elucidate why cities exhibit significant disparities in pandemic response effectiveness and complia...

Authors: Wen Hong and Beier Zhou

Citation: *Health Research Policy and Systems* 2025 23:53 Content type: Research Published on: 29 April 2025

Human Gene Therapy

Volume 36, Issue 7-8 / April 2025 https://www.liebertpub.com/toc/hum/36/7-8 [Reviewed earlier]

Humanitarian Practice Network

https://odihpn.org/ Featured Publications [No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 21 Issue 1, 2025 https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList Selected Content [Reviewed earlier]

Immunity

Apr 08, 2025 Volume 58 Issue 4 p767-1032 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/ [Accessed 04 May 2025] [No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content]

[Accessed 04 May 2025]

Reliability and validity study of the "5Cs" hesitancy scale for maternal influenza vaccination among pregnant and postpartum women

Maternal influenza vaccine hesitancy plays a vital role in the low rates of vaccination. However, instruments to appropriately assess perinatal influenza vaccine hesitancy are unavailable. This study aimed to ...

Authors: Fanyu Zeng, Bingcheng Du, Hong Jiang, Min Zheng, Xiu Qiu, Fen Li, Nianhua Yi, Yinglan Wu, Yuanying Ma, Changhui Li, Chunyi Gu, Lei Wang, Fengyun Yang, Longmei Jin, Yanran Yang and Xu Oian

Citation: Infectious Diseases of Poverty 2025 14:34

Content type: Research Article Published on: 30 April 2025

International Health

Volume 17, Issue 3, May 2025 https://academic.oup.com/inthealth/issue/17/3 [New issue; No digest content identified]

International Human Rights Law Review

Volume 13 (2024): Issue 2 (Dec 2024) https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml [Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 12 No. 5 (2025): May 2025

https://www.ijcmph.com/index.php/ijcmph/issue/view/124

Original Research Articles

Knowledge and practice of primary healthcare workers on the routine childhood immunization schedule in Osun State

Waheed O. Ogunwale, John S. Oladapo, Peter A. Ojo, Peter C. Okanya, Kikelomo O. Fasheyi, Olubukunmi G. Ogunrinu, Nafisat D. Olajide 1978-1985

DOI: 10.18203/2394-6040.ijcmph20251349

<u>Challenges in the COVID-19 vaccination among health care providers in Yangon region, Myanmar: a qualitative study</u>

Khaing Lay Mon, Swe Mar Myint Lwin, Le Thandar Soe, Megan Khoo 2036-2042

DOI: 10.18203/2394-6040.ijcmph20251355

International Journal of Epidemiology

Volume 54, Issue 2, April 2025 https://academic.oup.com/ije/issue/54/2 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 18 Issue 1 2025

https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1

Table of contents [Reviewed earlier]

JAMA

April 22/29, 2025, Vol 333, No. 16, Pages 1373-1466 https://jamanetwork.com/journals/jama/currentissue [Reviewed earlier]

JAMA Health Forum

April 2025, Vol 6, No. 4 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

April 2025, Vol 179, No. 4, Pages 359-482 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

April 2025 - Volume 23 - Issue 4 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

May 2025 Volume 76 Issue 5 p749-960 https://www.jahonline.org/current Original Articles

A Sociocultural Perspective of HPV Vaccine-Related Decision Making Among Immigrant Mothers in the United States

Obianuju Aliche, Mia Liza A. Lustria, Mary A. Gerend Published online: February 20, 2025 p897-904

Journal of Artificial Intelligence Research

Vol. 82 (2025) https://www.jair.org/index.php/jair Contents [Reviewed earlier]

Journal of Community Health

Volume 50, Issue 2 April 2025 https://link.springer.com/journal/10900/volumes-and-issues/50-2 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 8 No. 01 (2025)

https://www.cmro.in/index.php/jcmro/issue/view/91

[Reviewed earlier]

Journal of Development Economics

Volume 174 May 2025

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/174/suppl/C

Research article Open access

Beyond the records: Data quality and COVID-19 vaccination progress in low- and middle-income countries

Yannick Markhof, Philip Wollburg, Alberto Zezza Article 103449

Short communication Abstract only

<u>Can SMS interventions increase vaccination? Evidence from the COVID-19 pandemic in Kenya</u>

Kevin Carney, Leah R. Rosenzweig, Wendy N. Wong, Florence Akech, ... Elisa M. Maffioli Article 103469

Journal of Empirical Research on Human Research Ethics

Volume 20 Issue 1-2, February-April 2025 http://journals.sagepub.com/toc/jre/current [Reviewed earlier]

Journal of Epidemiology & Community Health

March 2025 - Volume 79 - 3 https://jech.bmj.com/content/79/3 [Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 18, Issue 2 June 2025 https://onlinelibrary.wiley.com/toc/17565391/current [Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 3 (2024) http://www.tandfonline.com/toc/rjge20/current **Special Issue: 20th Anniversary Forum** [Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 36, Number 1, February 2025 https://muse.jhu.edu/issue/54278 Table of Contents [Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 27, Issue 2 April 2025 https://link.springer.com/journal/10903/volumes-and-issues/27-2 [Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 23, Issue 1 (2025) https://www.tandfonline.com/toc/wimm20/current [Reviewed earlier]

Journal of International Development

Volume 37, Issue 3 Pages: 1-833 April 2025 https://onlinelibrary.wiley.com/toc/10991328/current [New issue; No digest content identified]

Journal of Medical Ethics

April 2025 - Volume 51 - 4 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 12, Issue 1 (2025) https://institutionalrepository.aah.org/jpcrr/ [New issue; No digest content identified]

The Journal of Pediatrics

Volume 277 February 2025 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C [Reviewed earlier]

Journal of Pharmaceutical Policy and Practice

Volume 18, 2025 Issue 1 https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList [Reviewed earlier]

Journal of Public Health Management & Practice

March/April 2025 - Volume 31 - Issue 2 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 46, Issue 1 March 2025 https://link.springer.com/journal/41271/volumes-and-issues/46-1 [Reviewed earlier]

Journal of the Royal Society - Interface

April 2025 Volume 22 Issue 225 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 32, Issue 3, April 2025 https://academic.oup.com/jtm/issue [Reviewed earlier]

Journal of Virology

Volume 99 • Number 2 • February 2025 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

May 03, 2025 Volume 405 Number 10489 p1555-1640 https://www.thelancet.com/journals/lancet/issue/current Editorial

The pandemic treaty: a milestone, but with persistent concerns

The Lancet

After more than 3 years of intense negotiations, <u>WHO member states</u> have finally reached a consensus on a new treaty to prevent, prepare for, and respond to pandemics. Initiated in 2021, negotiations over the terms of the legally binding agreement have been substantially delayed due to several contentious issues, including over how to ensure equitable access to vaccines, treatments, and diagnostics, particularly for low-income and middle-income countries. Tedros Adhanom Ghebreyesus, WHO Director-General, praised the treaty, stating that it shows "multilateralism is alive and well, and that in our divided world, nations can still work together to find common ground, and a shared response to shared threats". There was a real chance that no text would be agreed at all, and the finalisation of a draft on April 16 is an important milestone in global health.

The treaty codifies key approaches to pandemic prevention, preparedness, and response, including One Health, strong and resilient health systems and regulatory frameworks, protection of health-care workers, and the need for equity. It also establishes several new entities to put these principles into practice. A Pathogen Access and Benefit-sharing System will enable materials and genome sequences of pandemic pathogens to be shared and aims to promote equitable sharing of any resulting innovations, such as vaccines. However, shameful and unjust provisions present in earlier drafts of the treaty remain. The treaty states that countries would have to share only 20% of any vaccines, therapeutics, or diagnostics. 20% is better than nothing, but it does not equate to a truly equitable and just approach. COVID-19 saw a handful of high-income countries hoard vaccine doses acquired through bilateral deals with manufacturers. This situation not only undermined the WHO-led COVAX

initiative, but also contributed to mortality and morbidity in the many countries that relied heavily on inadequate donations. The treaty does little to stop some countries again largely monopolising life-saving health tools and services at the expense of others.

No new pandemic funding is included in the treaty. The draft agreement encourages states to leverage existing financing entities and prioritise domestic funding, and "promote, as appropriate, within relevant bilateral, regional and/or multilateral funding mechanisms, innovative financing measures, including transparent financial reprogramming plans for pandemic prevention, preparedness and response, especially for developing country Parties experiencing fiscal constraints". There is already a Pandemic Fund and development banks will likely have a role too. A Coordinating Financial Mechanism will be established to promote sustainable financing for the implementation of the agreement, but how exactly it will operate alongside existing financing instruments is unclear.

The issue of accountability is also concerning. The treaty establishes a Conference of the Parties (COP) to assess the implementation of the agreement and review its functioning every 5 years. However, the COP can only make non-binding recommendations. Furthermore, Article 6.4 notes that "each Party shall monitor its preparedness capacities, and periodically assess...the functioning and readiness of, and gaps in, its pandemic prevention, preparedness and response capacities". Lack of independent monitoring and robust enforcement mechanisms means that there are no clear consequences for countries that fail to comply with the terms. These issues risk selective adherence, undermining the effectiveness and fairness of the agreement.

Pandemics are global by definition and a grave threat to global health, as well as societies more widely. The <u>recent Lancet Global Health 2050 Commission</u> estimated that there is a roughly 50% chance that a new pandemic causing 25 million or more deaths will occur between now and 2050. An international set of obligations for countries is therefore essential. The pandemic treaty is only the second-ever legally binding international agreement negotiated by WHO, after the <u>Framework Convention on Tobacco Control</u>. It contains many good provisions and should be signed and ratified by every country after its presentation at the World Health Assembly in May. But the lack of accountability, coupled with the weak requirements on health technologies, means that the treaty will be unable to prevent repetition of one of the key failures seen during COVID-19—the voracious acquisition of key resources by a handful of powerful actors at the expense of all. When the next pandemic does arise, it will take more than the pandemic treaty to ensure a truly equitable response.

Comment

Measles: the urgent need for global immunisation and preparedness Krutika Kuppalli, Saad B Omer

Review

CONSORT 2025 statement: updated guideline for reporting randomised trialsSally Hopewell, et al.

Summary

Well designed and properly executed randomised trials are considered the most reliable evidence on the benefits of healthcare interventions. However, there is overwhelming evidence that the quality of reporting is not optimal. The CONSORT (Consolidated Standards of Reporting Trials) statement was designed to improve the quality of reporting and provides a minimum set of items to be included in a report of a randomised trial. CONSORT was first published in 1996, then updated in 2001 and 2010. Here, we present the updated CONSORT 2025 statement, which aims to account for recent methodological advancements and feedback from end users. We conducted a scoping review of the literature and developed a project-specific database of empirical and theoretical evidence related to CONSORT, to generate a list of potential changes to the checklist. The list was enriched with recommendations provided by the lead authors of existing CONSORT extensions (Harms, Outcomes,

Non-pharmacological Treatment), other related reporting guidelines (TIDieR) and recommendations from other sources (eg, personal communications). The list of potential changes to the checklist was assessed in a large, international, online, three-round Delphi survey involving 317 participants and discussed at a two-day online expert consensus meeting of 30 invited international experts. We have made substantive changes to the CONSORT checklist. We added seven new checklist items, revised three items, deleted one item, and integrated several items from key CONSORT extensions. We also restructured the CONSORT checklist, with a new section on open science. The CONSORT 2025 statement consists of a 30-item checklist of essential items that should be included when reporting the results of a randomised trial and a diagram for documenting the flow of participants through the trial. To facilitate implementation of CONSORT 2025, we have also developed an expanded version of the CONSORT 2025 checklist, with bullet points eliciting critical elements of each item. Authors, editors, reviewers, and other potential users should use CONSORT 2025 when writing and evaluating manuscripts of randomised trials to ensure that trial reports are clear and transparent.

The Lancet Child & Adolescent Health

Apr 2025 Volume 9 Number 4 p211-282, e10-e12 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Apr 2025 Volume 7 Number 4 e232-e294 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Apr 2025 Volume 13 Number 4 e599-e777 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Apr 2025 Volume 25 Number 4 p357-470, e191-e254 https://www.thelancet.com/journals/laninf/issue/current [Reviewed earlier]

Lancet Public Health

Apr 2025 Volume 10 Number 4 e264-e346 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Apr 2025 Volume 13 Number 4 p289-370, e20-e23 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 29, Issue 4 April 2025 https://link.springer.com/journal/10995/volumes-and-issues/29-4 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 45 Issue 3, April 2025 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 103, Issue 1 Pages: 1-241 March 2025 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Apr 02, 2025 Volume 33 Issue 4 p1305-1860 https://www.cell.com/molecular-therapy/current

In this issue

Sickle cell disease (SCD) and β -thalassemia are two of the most common β -hemoglobinopathies, genetic diseases that affect the β -globin chains of hemoglobin. A single mutation in β -globin gene (*HBB*) causes the characteristic dysfunctional hemoglobin protein in SCD, while over 300 mutations across HBB cause severe anemia and reduced β -globin levels in β -thalassemia. Homology-directed repair (HDR) is a promising approach to restore HBB expression. However, HDR can be challenging because the insert cannot be homologous to the endogenous gene, and synonymous codon-optimized, intron-less sequences may be inadequate.

Nature

Volume 641 Issue 8061, 1 May 2025 https://www.nature.com/nature/volumes/640/issues/8060 Editorial 30 Apr 2025

The end of AIDS is in sight: don't abandon PEPFAR now

The US administration should clear up the confusion over the future of a widely admired AIDS fund and push for Congress to reauthorize it.

Editorial 29 Apr 2025

Historic pandemic treaty is a triumph in a world being torn apart

Global agreement on a pandemic preparedness plan came against all the odds. Now all parties must follow good intentions with concrete actions.

Nature Biotechnology

Volume 43 Issue 4, April 2025 https://www.nature.com/nbt/volumes/43/issues/4 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed 04 May 2025) [Reviewed earlier]

Nature Genetics

Volume 57 Issue 4, April 2025 https://www.nature.com/ng/volumes/57/issues/4 [Reviewed earlier]

Nature Human Behaviour

Volume 9 Issue 4, April 2025 https://www.nature.com/nathumbehav/volumes/9/issues/4 [Reviewed earlier]

Nature Medicine

Volume 31 Issue 4, April 2025 https://www.nature.com/nm/volumes/31/issues/4 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 24 Issue 4, April 2025 https://www.nature.com/nrd/volumes/24/issues/4 [Reviewed earlier]

Nature Reviews Genetics

Volume 26 Issue 4, April 2025 https://www.nature.com/nrg/volumes/26/issues/4 [Reviewed earlier]

Nature Reviews Immunology

Volume 25 Issue 4, April 2025 https://www.nature.com/nri/volumes/25/issues/4 [Reviewed earlier]

New England Journal of Medicine

Volume 392 No. 17 May 1, 2025 https://www.nejm.org/toc/nejm/medical-journal [New issue; No digest content identified]

NEJM Evidence

Volume 4 No. 4 April 2025 https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 04 May 2025] [No new digest content identified]

Pediatrics

Volume 155, Issue 4 April 2025 https://publications.aap.org/pediatrics/issue/155/4 [Reviewed earlier]

PharmacoEconomics

Volume 43, Issue 5 May 2025 https://link.springer.com/journal/40273/volumes-and-issues/43-5 [New issue; No digest content identified]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 04 May 2025) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 04 May 2025) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 04 May 2025)

Association between national action and trends in antibiotic resistance: an analysis of 73 countries from 2000 to 2023

Peter Søgaard Jørgensen, Luong Nguyen Thanh, Ege Pehlivanoğlu, Franziska Klein, Didier Wernli, Dusan Jasovsky, Athena Aktipis, Robert R. Dunn, Yrjö Gröhn, Guillaume Lhermie, H. Morgan Scott, Eili Y. Klein

Research Article | published 30 Apr 2025 PLOS Global Public Health https://doi.org/10.1371/journal.pgph.0004127

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 04 May 2025)

SPIRIT 2025 statement: Updated guideline for protocols of randomised trials

An-Wen Chan, Isabelle Boutron, Sally Hopewell, David Moher, Kenneth F. Schulz, Gary S. Collins, Ruth Tunn, Rakesh Aggarwal, Michael Berkwits, Jesse A. Berlin, Nita Bhandari, Nancy J. Butcher, Marion K.

Campbell, Runcie C. W. Chidebe, Diana R. Elbourne, Andrew J. Farmer, Dean A. Fergusson, Robert M. Golub, Steven N. Goodman, Tammy C. Hoffmann, John P. A. Ioannidis, Brennan C. Kahan, Rachel L. Knowles, Sarah E. Lamb, Steff Lewis, Elizabeth Loder, Martin Offringa, Philippe Ravaud, Dawn P. Richards, Frank W. Rockhold, David L. Schriger, Nandi L. Siegfried, Sophie Staniszewska, Rod S. Taylor, Lehana Thabane, David J. Torgerson, Sunita Vohra, Ian R. White, Asbjørn Hróbjartsson Guidelines and Guidance | published 28 Apr 2025 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004589

Improving transparency in clinical trial reporting

Alison Farrell, On Behalf of the PLOS Medicine Editors Editorial | published 28 Apr 2025 PLOS Medicine https://doi.org/10.1371/journal.pmed.1004588

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 04 May 2025)

Proceedings of the second annual dengue endgame summit: A call to action

Céline S.C. Hardy, Lauren E. Bahr, Alan L. Rothman, Kathryn B. Anderson, Giovanna Barba-Spaeth, Daniela Weiskopf, Eng Eong Ooi, Ernesto T.A. Marques, Mattia Bonsignori, Alan D.T. Barrett, Beth D. Kirkpatrick, Priscila M.S. Castanha, Marco Hamins-Puertolas, Rebecca C. Christofferson, George Dimopoulos, Fabiano Oliveira, Lillian W. Chiang, Albert I. Ko, Bhagwat Gunale, Prasad Kulkarni, T. Alex Perkins, Ilaria Dorigatti, Telisa Stewart, Jana Shaw, Michael A. Johansson, Stephen J. Thomas, Adam T. Waickman

Policy Platform | published 28 Apr 2025 PLOS Neglected Tropical Diseases https://doi.org/10.1371/journal.pntd.0013028

PLoS One

http://www.plosone.org/

[Accessed 04 May 2025]

Are people willing to take regular vaccinations? A qualitative study among diverse ethnic groups in Hong Kong

Yan Li, Ivy Yan Zhao, Wenze Lu, Sau Fong Leung, Daniel Bressington, Lin Yang, Yao Jie Xie, Mengqi Li, Angela Y. M. Leung

Research Article | published 02 May 2025 PLOS ONE

https://doi.org/10.1371/journal.pone.0318631

<u>Determinants of incomplete immunization among 12–23 months old children in Ethiopia: A multilevel analysis</u>

Sofiya Ayalew Kebede, Yawkal Tsega, Niguss Cherie, Asressie Molla, Chad Stecher Research Article | published 29 Apr 2025 PLOS ONE https://doi.org/10.1371/journal.pone.0321947

<u>Exploring vaccination attitudes in African communities in Canada: A mixed-methods study protocol</u>

Obidimma Ezezika, Zantae Pellitier, Sonia Muhimpundu, Christian Daboud, Meron Mengistu, Omolola Olorunbiyi, Christian Hines, Mekoya Wondrad, Joanne Kearon, Reforce Okwei, Kingsley Anukam, Dominic Alaazi, Godwin Arku

Study Protocol | published 28 Apr 2025 PLOS ONE

https://doi.org/10.1371/journal.pone.0319584

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 04 May 2025] [No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States

May 6, 2025 | vol. 122 | no. 18 https://www.pnas.org/toc/pnas/122/18 [New issue; No digest content identified]

PNAS Nexus

Volume 4, Issue 3, March 2025 https://academic.oup.com/pnasnexus/issue/4/3 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 40 - Issue 2 - April 2025 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [Reviewed earlier]

Preventive Medicine

Volume 193 April 2025 https://www.sciencedirect.com/journal/preventive-medicine/vol/193/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

April 2025 Volume 292 Issue 2045 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

Public Health

Volume 241 Pages 1-186 (April 2025) https://www.sciencedirect.com/journal/public-health/vol/241/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 18, Issue 1, April 2025 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2025, Vol. 28, No. 1 https://karger.com/phg/issue/28/1

[Reviewed earlier]

Public Health Reports

Volume 140 Issue 1, January/February 2025 https://journals.sagepub.com/toc/phrg/140/1 [Reviewed earlier]

Qualitative Health Research

Volume 35 Issue 4-5, April 2025 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 21 Issue 2, April 2025 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 04 May 2025] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles 28 Apr 2025

<u>Delivering rapid, up-to-date, high-quality evidence is feasible during health emergencies:</u>
<u>PAHO living systematic review of 305 COVID-19 potential therapeutics</u>

Review | English |

28 Apr 2025

Agreement on pandemics and access to vaccines for low- and middle-income countries

Opinion and analysis | Portuguese |

28 Apr 2025

<u>Inclusive digital transformation: the scenario of digital service usage by women in Brazil</u> Special report | Portuguese |

Risk Analysis

Volume 45, Issue 4 Pages: 723-967 April 2025 https://onlinelibrary.wiley.com/toc/15396924/current

Special Issue: Artificial Intelligence for Risk Analysis and the Risks of AI

[Reviewed earlier]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 04 May 2025]
[No new digest content identified]

Royal Society Open Science

April 2025 Volume 12 Issue 4 https://royalsocietypublishing.org/toc/rsos/current [Reviewed earlier]

Science

Volume 388| Issue 6746| 1 May 2025 https://www.science.org/toc/science/current [New issue; No digest content identified]

Science and Engineering Ethics

Volume 31, Issue 2 April 2025 https://link.springer.com/journal/11948/volumes-and-issues/31-2 [Reviewed earlier]

Science Translational Medicine

Volume 17| Issue 796| 30 Apr 2025 https://www.science.org/toc/stm/current [New issue; No digest content identified]

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 04 May 2025] [No new digest content identified]

Social Science & Medicine

Volume 370 April 2025 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 04 May 2025] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 46, Issue 2 April 2025 https://link.springer.com/journal/11017/volumes-and-issues/46-2 [Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 64 March—April 2025 https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C [Reviewed earlier]

Tropical Medicine & International Health

Volume 30, Issue 4 Pages: i-iv, 231-321 April 2025 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

Vaccine

Volume 53 19 April 2025 https://www.sciencedirect.com/journal/vaccine/vol/53/suppl/C [Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines [Accessed 04 May 2025] Open Access Review

Dengue Vaccine Development and Deployment into Routine Immunization

by Annelies Wilder-Smith, Thomas Cherian and Joachim Hombach Vaccines 2025, 13(5), 483; https://doi.org/10.3390/vaccines13050483 - 29 Apr 2025 **Abstract**

Dengue has emerged as a significant global health threat. Despite decades of research, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—have been licensed to date, with limited implementation. This paper explores and outlines strategies for integrating dengue vaccines into routine immunization programs, particularly [...]

Value in Health

April 2025 Volume 28 Issue 4 p489-670 https://www.valueinhealthjournal.com/current [Reviewed earlier]

World Development

Volume 191 July 2025 https://www.sciencedirect.com/journal/world-development/vol/191/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch

:: <u>Pre-Print Servers</u>

Pre-Print Servers

arxiv

::::::

https://arxiv.org/

[Accessed 04 May 2025]

[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]

arXiv:2504.21580 [pdf, other]

Multigenerational Effects of Smallpox Vaccination

Volha Lazuka, Peter Sandholt Jensen

Can the effects of childhood vaccination extend across three generations? Using Swedish data spanning 250 years, we estimate the impact of smallpox vaccination on longevity, disability, and occupational achievements. Employing mother fixed-effects, difference-in-differences, and shift-share instrumental-variables designs, we find that vaccination improves health and economic outcomes for at least two subsequent generations. Causal mediation analysis reveals that these benefits arise from improved health behaviors and epigenetic factors. Even in milder disease environments as seen today, vaccination delivers lasting advantages, demonstrating its long-term benefits beyond epidemic contexts. These findings highlight the benefits of early-life health interventions lasting for subsequent generations.

Gates Open Research

https://gatesopenresearch.org/browse/articles [Accessed 04 May 2025] [No new digest content identified]

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 04 May 2025] [Filter: All articles]

Mpox severity and mortality in the most endemic focus in Africa: a systematic review and meta-analysis (1970-2024)

Fabrice Zobel Lekeumo Cheuyem, Armel Zemsi, Jonathan Hangi Ndungo, Chabeja Achangwa, Davy Romeo Takpando-le-grand, Jessy Goupeyou-Youmsi, Solange Dabou, Mohamadou Adama, Ariane Nouko, Marie Angel Mbang, Edwige Omona Guissana, Rick Tchamani, Vanessa Monique Mballa Assiene, Ethel Eno, Constantine Asahngwa, Saralees Nadarajah

medRxiv 2025.04.07.25325410; doi: https://doi.org/10.1101/2025.04.07.25325410 Revision

<u>Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21/Matrix-M: a modelling study</u>

Kelly McCain, Hillary Topazian, Joseph D Challenger, Lucy C Okell, Peter Winskill, Azra C Ghani medRxiv 2025.05.01.25326809; doi: https://doi.org/10.1101/2025.05.01.25326809

Research on Public Risk Perception and Panic Psychology in the Post-Emergency Phase of Major Public Health Crises

Ge Shi, Xingtong Men, Jiayi Li, Chengzi Huang, liyi Ma, Chenchen Xia medRxiv 2025.04.29.25325326; doi: https://doi.org/10.1101/2025.04.29.25325326

<u>System-Wide Investments Enhance HIV, TB and Malaria Control in Malawi and Deliver</u> <u>Greater Health Impact</u>

Tara D Mangal, Sakshi Mohan, Margherita Molaro, Joseph Collins, Tim Colbourn, Eva Janoušková, Rachel E Murray-Watson, Dominic Nkhoma, Andrew Phillips, Bingling She, Pakwanja D Twea, Simon Walker, Paul Revill, Timothy B. Hallett

medRxiv 2025.04.29.25326667; doi: https://doi.org/10.1101/2025.04.29.25326667

The potential global impact and cost-effectiveness of next-generation influenza vaccines: a modelling analysis

Lucy Goodfellow, Simon R Procter, Mihaly Koltai, Naomi R Waterlow, Johnny A N Filipe, Carlos K H Wong, Edwin van Leeuwen, WHO Technical Advisory Group for the Full Value of Influenza Vaccines Assessment and project team, Next-generation influenza vaccine impact modelling contributors, Rosalind M Eggo, Mark Jit

medRxiv 2024.09.19.24313950; doi: https://doi.org/10.1101/2024.09.19.24313950 Revision

Who would take part in a pandemic preparedness cohort study? The role of vaccinerelated affective polarisation: cross-sectional survey

Aziz Mert Ipekci, Eva Maria Hodel, Maximilian Filsinger, Selina Wegmüller, Simone Schuller, Markus Freitag, Annika Frahsa, Gilles Wandeler, Nicola Low medRxiv 2025.04.26.25326349; doi: https://doi.org/10.1101/2025.04.26.25326349

Estimating the impact of the RTS,S/AS01 malaria vaccine in Benin: A mathematical modelling study

Sena Alohoutade, Rachel Hounsell, Codjo Dandonougbo, Rock Aikpon, Jules Degila, Sheetal Silal medRxiv 2024.07.20.24310712; doi: https://doi.org/10.1101/2024.07.20.24310712 Revision

Whole Genome Sequencing for the Diagnosis of Rare Disorders

Antonio Victor Campos Coelho, Rafael Sales de Albuquerque, Catarina dos Santos Gomes, José Bandeira do Nascimento Junior, Gustavo Santos de Oliveira, Livia Maria Silva Moura, Luciana Souto Mofatto, Rafael Lucas Muniz Guedes, Rodrigo Araújo Sequeira Barreiro, Marcel Pinheiro Caraciolo, Ana Paula de Andrade Oliveira, Anne Caroline Barbosa Teixeira, Bruna Mascaro Cordeiro de Azevedo, Carolina Dias Carlos, Lucas Santos de Santana, Marina Cadena da Matta, Matheus Martinelli Lima, Nuria Bengala Zurro, Renata Yoshiko Yamada, Vivian Pedigone Cintra, Gabriela Pereira Campilongo, Gabriela Borges Cherulli Colichio, Renata Martins Ribeiro da Silva, Caio Robledo D'Angioli Costa Quaio, Carolina Araújo Moreno, Eduardo Perrone, Jéssica Grasiela Araújo Espolaor, Joana Rosa Marques Prota, José Ricardo Magliocco Ceroni, Kelin Chen, Luiza do Amaral Virmond, Marina de Franca Basto Silva, Michele Patricia Migliavacca, Renata Moldenhauer Minillo, Thiago Yoshinaga Tonholo Silva, Karla de Oliveira Pelegrino, Ana Luiza Garcia Cunha, Joziele de Souza Lima, Anete Sevciovic Grumach, Caio Parente Barbosa, Angelina Xavier Acosta, Paula Brito Corrêa, Denise Pontes Cavalcanti, Carlos Eduardo Steiner, Erlane Marques Ribeiro, Wallace William da Silva Meireles, Giselle Maria Araujo Felix Adjuto, Ida Vanessa Doederlein Schwartz, Têmis Maria Felix, Irma Cecilia Douglas Paes Barreto, Antonette Souto El-Husny, Jussara Melo de Cerqueira Maia, Vera Maria Dantas, Lúcia Helena de Oliveira Cordeiro, Luisa Zagne Braz, Magda Maria Sales Carneiro Sampaio, Mara Lucia Schmitz Ferreira Santos, Marco Antonio Curiati, Maria Teresinha de Oliveira Cardoso, Maria Teresa Alves da Silva Rosa, Mariana Paes Leme Ferriani, Ester Silveira Ramos, Paula Teixeira Lyra, Raquel Tavares Boy da Silva, Anna Cândida Ximenes de Mendonça Sobreira, Tatiana Regia Suzana Amorim Boa Sorte, Melissa Rossi Calvão Dumas, Thaís Bomfim Teixeira, Vandré Cabral Gomes Carneiro, Patrícia Silva Mota, Tatiana Ferreira de Almeida, João Bosco Oliveira

medRxiv 2025.04.25.25326373; doi: https://doi.org/10.1101/2025.04.25.25326373

Systematic literature review of the use of generative AI in health economic evaluation

Steve Sharp, Kusal Lokuge, Jamie Elvidge, Tom Hudson, Dalia Dawoud medRxiv 2025.04.25.25326412; doi: https://doi.org/10.1101/2025.04.25.25326412

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]
[No new digest content identified]

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles [Accessed 04 May 2025] [No new digest content identified]

* * * *

Think Tanks

Brookings [to 04 May 2025] http://www.brookings.edu/ Reports, Events No new digest content identified.

Center for Global Development [to 04 May 2025]

https://www.cgd ev.org/ All Research No new digest content identified.

Chatham House [to 04 May 2025] https://www.chathamhouse.org/ Selected Analysis, Comment, Events No new digest content identified.

Council on Foreign Relations [to 04 May 2025]

https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 04 May 2025]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 04 May 2025]

https://www.kff.org/search/?post_type=press-release

Newsroom

Most of the Public Oppose Major Federal Cuts to Health Agencies and Programs and Say They Have Been Made "Recklessly"

May 1, 2025 News Release

McKinsey Global Institute [to 04 May 2025]

https://www.mckinsey.com/mgi/overview
Latest Research
No new digest content identified.

ODI [Overseas Development Institute] [to 04 May 2025]

https://odi.org/en/publications/ Publications [Selected] No new digest content identified.

Pew Research Center [to 04 May 2025]

https://www.pewresearch.org/ Latest Publications [Selected] Report Apr 24, 2025 Report May 1, 2025

Majorities of Americans Support Several - But Not All - Types of Foreign Aid

Most Americans say the U.S. should give humanitarian aid to other countries, and majorities endorse aid supporting economic development and democracy.

Rand [to 04 May 2025]

https://www.rand.org/pubs.html Published Research [Selected] Research Apr 28, 2025

The Evolution of United States Governance Policies for Research Using Pathogens with Enhanced Pandemic Potential

In response to 2012 studies enhancing a deadly pathogen's transmissibility, the U.S. and research community established policies to oversee research on enhanced pathogens with pandemic potential.

Urban Institute [to 04 May 2025] https://www.urban.org/publications **New Research Publications - Selected**

World Economic Forum [to 04 May 2025]

https://agenda.weforum.org/press/ Media [Selected] No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

No new digest content identified.

* * * *

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

:::::::

Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.